These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15620855)

  • 1. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis.
    Teunissen CE; Dijkstra C; Polman C
    Lancet Neurol; 2005 Jan; 4(1):32-41. PubMed ID: 15620855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis.
    Hein Née Maier K; Köhler A; Diem R; Sättler MB; Demmer I; Lange P; Bähr M; Otto M
    Neurosci Lett; 2008 May; 436(1):72-6. PubMed ID: 18359164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.
    Szalardy L; Zadori D; Simu M; Bencsik K; Vecsei L; Klivenyi P
    J Neurol Sci; 2013 Aug; 331(1-2):38-42. PubMed ID: 23706476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological indicators of the neurodegenerative phase of multiple sclerosis.
    Zaffaroni M
    Neurol Sci; 2003 Dec; 24 Suppl 5():S279-82. PubMed ID: 14652789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability.
    Semra YK; Seidi OA; Sharief MK
    J Neuroimmunol; 2002 Jan; 122(1-2):132-9. PubMed ID: 11777552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some markers of neuronal damage in cerebrospinal fluid of multiple sclerosis patients in relapse.
    Mitosek-Szewczyk K; Gordon-Krajcer W; Flis D; Stelmasiak Z
    Folia Neuropathol; 2011; 49(3):191-6. PubMed ID: 22101952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau protein: a possible prognostic factor in optic neuritis and multiple sclerosis.
    Frederiksen J; Kristensen K; Bahl JM; Christiansen M
    Mult Scler; 2012 May; 18(5):592-9. PubMed ID: 21969238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders.
    Shafaati M; Solomon A; Kivipelto M; Björkhem I; Leoni V
    Neurosci Lett; 2007 Sep; 425(2):78-82. PubMed ID: 17822846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid total tau protein levels in patients with multiple sclerosis.
    Terzi M; Birinci A; Cetinkaya E; Onar MK
    Acta Neurol Scand; 2007 May; 115(5):325-30. PubMed ID: 17489943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofilaments as biomarkers in multiple sclerosis.
    Teunissen CE; Khalil M
    Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism.
    Lütjohann D; von Bergmann K
    Pharmacopsychiatry; 2003 Sep; 36 Suppl 2():S102-6. PubMed ID: 14574622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
    Otto M; Lewczuk P; Wiltfang J
    Methods; 2008 Apr; 44(4):289-98. PubMed ID: 18374272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.
    Bartosik-Psujek H; Archelos JJ
    J Neurol; 2004 Apr; 251(4):414-20. PubMed ID: 15083285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype.
    Wallin A; Blennow K; Rosengren L
    Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S102-5. PubMed ID: 10609688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
    Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A
    J Neuroimmunol; 2010 Mar; 220(1-2):114-9. PubMed ID: 20117845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.
    Trentini A; Comabella M; Tintoré M; Koel-Simmelink MJ; Killestein J; Roos B; Rovira A; Korth C; Ottis P; Blankenstein MA; Montalban X; Bellini T; Teunissen CE
    J Neurol; 2014 Dec; 261(12):2338-43. PubMed ID: 25228004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.